Relmada Therapeutics Inc (NASDAQ: RLMD) kicked off on Tuesday, up 26.79% from the previous trading day, before settling in for the closing price of $1.12. Over the past 52 weeks, RLMD has traded in a range of $0.24-$3.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 0.68% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 27.17%. With a float of $26.44 million, this company’s outstanding shares have now reached $33.19 million.
Relmada Therapeutics Inc (RLMD) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Relmada Therapeutics Inc is 20.34%, while institutional ownership is 24.88%. The most recent insider transaction that took place on Aug 27 ’25, was worth 86,735. In this transaction Chief Executive Officer of this company bought 129,455 shares at a rate of $0.67, taking the stock ownership to the 944,024 shares. Before that another transaction happened on Aug 26 ’25, when Company’s Chief Executive Officer bought 80,545 for $0.62, making the entire transaction worth $49,938. This insider now owns 814,569 shares in total.
Relmada Therapeutics Inc (RLMD) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.59 earnings per share (EPS), higher than consensus estimate (set at -0.83) by 0.24.
Relmada Therapeutics Inc (NASDAQ: RLMD) Trading Performance Indicators
Take a look at Relmada Therapeutics Inc’s (RLMD) current performance indicators. Last quarter, stock had a quick ratio of 4.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.21, a number that is poised to hit -0.45 in the next quarter
Technical Analysis of Relmada Therapeutics Inc (RLMD)
Let’s dig in a bit further. During the last 5-days, its volume was 5.05 million. That was better than the volume of 1.24 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 87.17%.
During the past 100 days, Relmada Therapeutics Inc’s (RLMD) raw stochastic average was set at 88.80%, which indicates a significant increase from 85.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1200 in the past 14 days, which was higher than the 0.0810 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6472, while its 200-day Moving Average is $0.6645. However, in the short run, Relmada Therapeutics Inc’s stock first resistance to watch stands at $1.6389. Second resistance stands at $1.8579. The third major resistance level sits at $2.1473. If the price goes on to break the first support level at $1.1305, it is likely to go to the next support level at $0.8411. The third support level lies at $0.6221 if the price breaches the second support level.
Relmada Therapeutics Inc (NASDAQ: RLMD) Key Stats
The company with the Market Capitalisation of 47.13 million has total of 33,192K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -79,980 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -9,870 K.
